Literature DB >> 9687887

Endothelin-1 and 5-fluorouracil-induced cardiotoxicity.

C Porta1, M Moroni, S Ferrari, G Nastasi.   

Abstract

Cardiotoxicity is an uncommon side-effect of 5-FU-based chemotherapy. Coronary artery vasospasms have been postulated to be involved in the pathogenesis of this rare but serious problem. We found high plasma levels of ET-1, a potent natural vasoconstrictor, in two patients who experienced two of the commonest clinical manifestations of 5-FU-induced cardiac toxicity--i.e., angina pectoris and chronic heart failure. We, therefore, propose ET-1 as the ultimate mediator of this toxicity, even though the mechanism of ET-1 increase in peripheral venous blood is still unknown. Finally, another important question still remains unresolved: is the release of ET-1 from normal coronary endothelial cells the prime cause or simply the consequence of 5-FU-related cardiotoxicity?

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9687887

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  15 in total

1.  Variant angina pectoris associated with FOLFOX4 therapy.

Authors:  Hiromichi Yamane; Minoru Matsubara; Shigeki Umemura; Toshimitsu Suwaki; Haruhito Kamei; Nagio Takigawa; Katsuyuki Kiura; Mitsune Tanimoto
Journal:  World J Gastrointest Oncol       Date:  2011-11-15

Review 2.  Cancer chemotherapy and cardiac arrhythmias: a review.

Authors:  Juan Tamargo; Ricardo Caballero; Eva Delpón
Journal:  Drug Saf       Date:  2015-02       Impact factor: 5.606

3.  Coronary vasospasm secondary to 5-Fluorouracil and its management: case report.

Authors:  Mustafa Yildirim; Cem Parlak; Cem Sezer; Ramazan Eryilmaz; Cetin Kaya; Mustafa Yildiz
Journal:  Eurasian J Med       Date:  2011-04

Review 4.  Cancer Chemotherapy-Induced Sinus Bradycardia: A Narrative Review of a Forgotten Adverse Effect of Cardiotoxicity.

Authors:  Juan Tamargo; Ricardo Caballero; Eva Delpón
Journal:  Drug Saf       Date:  2022-01-13       Impact factor: 5.606

5.  Acute coronary syndrome associated with continuous 5-Fluorouracil infusion in a patient with metastatic colorectal cancer-a case report with a discussion on this clinical dilemma.

Authors:  Carlos Eduardo Paiva; Bianca Sakamoto Ribeiro Paiva; Rodrigo Garita; Odair Carlito Michelin; Katashi Okoshi
Journal:  J Gastrointest Cancer       Date:  2009

6.  Reversible cardiogenic shock following 5-fluorouracil infusion.

Authors:  Charles Ferté; Carlos Gomez Roca; Yohann Loriot; Rastislav Bahleda; Cristian Moldovan; Ariel Cohen; Hassan Izzedine; Jean-Charles Soria; Stephane Ederhy
Journal:  Invest New Drugs       Date:  2009-06-05       Impact factor: 3.850

Review 7.  Exercise and Aerobic Fitness to Reduce Cancer-Related Cardiovascular Toxicity.

Authors:  Umberto Campia; Ana Barac
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-07

Review 8.  Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond.

Authors:  Rohit Moudgil; Edward T H Yeh
Journal:  Can J Cardiol       Date:  2016-02-02       Impact factor: 5.223

9.  5-Fluorouracil induces arterial vasoconstrictions but does not increase angiotensin II levels.

Authors:  Taflan Salepci; Mesut Seker; Huseyin Uyarel; Mahmut Gumus; Ahmet Bilici; Bala Basak Oven Ustaalioğlu; Akin Oztürk; Berkant Sonmez; Asuman Orcun; Mustafa Ozates; Rahmi Irmak; Mustafa Yaylaci
Journal:  Med Oncol       Date:  2009-05-05       Impact factor: 3.064

10.  Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.

Authors:  Christos Kosmas; Manolis S Kallistratos; Petros Kopterides; John Syrios; Helias Skopelitis; Nicolaos Mylonakis; Athanasios Karabelis; Nicolas Tsavaris
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-17       Impact factor: 4.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.